{"id":727029,"date":"2023-01-31T06:53:01","date_gmt":"2023-01-31T11:53:01","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/novabay-pharmaceuticals-to-present-at-the-virtual-sequire-biotechnology-conference-on-february-2-2023\/"},"modified":"2023-01-31T06:53:01","modified_gmt":"2023-01-31T11:53:01","slug":"novabay-pharmaceuticals-to-present-at-the-virtual-sequire-biotechnology-conference-on-february-2-2023","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/novabay-pharmaceuticals-to-present-at-the-virtual-sequire-biotechnology-conference-on-february-2-2023\/","title":{"rendered":"NovaBay Pharmaceuticals to Present at the Virtual Sequire Biotechnology Conference on February 2, 2023"},"content":{"rendered":"

<\/p>\n

NovaBay Pharmaceuticals to Present at the Virtual Sequire Biotechnology Conference on February 2, 2023<\/b><\/p>\n

EMERYVILLE, Calif.–(BUSINESS WIRE<\/a>)–NovaBay\u00ae<\/sup> Pharmaceuticals, Inc<\/a>. (NYSE American: NBY) announces that Justin Hall, CEO, will present a company overview at the virtual Sequire Biotechnology Conference on Thursday, February 2 at 2:30 p.m. Eastern time. To register for the event, visit the Sequire Biotechnology website<\/a>.\n<\/p>\n

\n\u201cWe closed 2022 with one of our best quarters ever for Avenova\u00ae<\/sup> unit sales. Looking into 2023, we are increasing our focus on our safe, effective wound care products, which we expect will become an important contributor to our business,\u201d said Mr. Hall. \u201cWe are excited to share an update on our opportunities with investors attending this conference.\u201d\n<\/p>\n

\nAn archived webcast of the presentation will be available on the NovaBay website<\/a>. NovaBay will report 2022 fourth quarter and full year financial results on March 23, 2023.\n<\/p>\n

About Sequire<\/b><\/p>\n

\nSequire is a premier investor intelligence and communications platform where companies can track their investors\u2019 behaviors and trends and use those insights to engage current and potential investors across marketing channels. More information is available at srax.com<\/a> and mysequire.com<\/a>.\n<\/p>\n

About NovaBay Pharmaceuticals, Inc.:<\/b><\/p>\n

\nNovaBay Pharmaceuticals, Inc. develops and sells scientifically created and clinically proven eyecare and skincare products. NovaBay\u2019s leading product, Avenova\u00ae<\/sup> Antimicrobial Lid & Lash Solution, is often prescribed by eyecare professionals for blepharitis and dry-eye disease and is also available directly to eyecare consumers through online distribution channels such as Amazon. DERMAdoctor\u00ae<\/sup> offers more than 30 OTC dermatologist-developed skincare products through the DERMAdoctor website, well-known traditional and digital beauty retailers, and international distributors. NovaBay also manufactures and sells effective, yet gentle and non-irritating wound care products. The PhaseOne\u00ae<\/sup> brand is distributed through commercial partners in the U.S. for professional use only, and the NeutroPhase\u00ae<\/sup> brand is distributed in China by Pioneer Pharma (Hong Kong) Company Ltd.\n<\/p>\n

NovaBay Pharmaceuticals Forward-Looking Statements<\/b><\/p>\n

\nExcept for historical information herein, matters set forth in this press release may be forward looking within the meaning of the \u201csafe harbor\u201d provisions of the Private Securities Litigation Reform Act of 1995, including statements about the commercial progress and future financial performance of NovaBay Pharmaceuticals, Inc. This release contains forward-looking statements that are based upon management\u2019s current expectations, assumptions, estimates, projections and beliefs. These statements include, but are not limited to, statements regarding our business strategies, current partnerships, marketing efforts, and any future revenue that may result from such partnerships and related marketing initiatives, as well as generally the Company\u2019s expected future financial results. These statements involve known and unknown risks, uncertainties and other factors that may cause actual results or achievements to be materially different and adverse from those expressed in or implied by the forward-looking statements. Factors that might cause or contribute to such differences include, but are not limited to, risks and uncertainties relating to the size of the potential market for our products, the possibility that the available market for the Company\u2019s products will not be as large as expected, the Company\u2019s products will not be able to penetrate one or more targeted markets, and revenues will not be sufficient to meet the Company\u2019s cash needs. Other risks relating to NovaBay\u2019s business, including risks that could cause results to differ materially from those projected in the forward-looking statements in this press release, are detailed in NovaBay\u2019s latest Form 10-Q\/K filings and Registration Statement on Form S-1 filing with the Securities and Exchange Commission, especially under the heading \u201cRisk Factors.\u201d The forward-looking statements in this release speak only as of this date, and NovaBay disclaims any intent or obligation to revise or update publicly any forward-looking statement except as required by law.\n<\/p>\n

Socialize and Stay Informed on NovaBay<\/b>\u2019s Progress
\n
<\/b>Like us on Facebook
\n<\/a>
Follow us on Twitter
\n<\/a>
Connect with NovaBay on LinkedIn
\n<\/a>
Visit NovaBay\u2019s Website<\/a><\/p>\n

Avenova Purchasing Information
\n
<\/b>For NovaBay Avenova purchasing information:
\n
Please call 800-890-0329 or email sales@avenova.com
\n<\/a>
Avenova.com<\/a><\/p>\n

DERMAdoctor Purchasing Information
\n
<\/b>For DERMAdoctor purchasing information:
\n
Please call 877-337-6237 or email service@dermadoctor.com
\n<\/a>
DERMAdoctor.com<\/a><\/p>\n

\"\"<\/p>\n

View source version on businesswire.com: <\/span>https:\/\/www.businesswire.com\/news\/home\/20230131005342\/en\/<\/a><\/span><\/p>\n

NovaBay Contact
\n<\/b>
Justin Hall
\n
Chief Executive Officer and General Counsel
\n
510-899-8800
\n
jhall@novabay.com<\/a><\/p>\n

Investor Contact
\n<\/b>
LHA Investor Relations
\n
Jody Cain
\n
310-691-7100
\n
jcain@lhai.com<\/a><\/p>\n

KEYWORDS:<\/b> California United States North America<\/p>\n

INDUSTRY KEYWORDS:<\/b> Cosmetics Retail Health Pharmaceutical Optical Biotechnology<\/p>\n

MEDIA:<\/b><\/p>\n\n\n\n\n
Logo<\/b><\/font><\/td>\n<\/tr>\n
\"Logo\"<\/td>\n<\/tr>\n
<\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"

NovaBay Pharmaceuticals to Present at the Virtual Sequire Biotechnology Conference on February 2, 2023 EMERYVILLE, Calif.–(BUSINESS WIRE)–NovaBay\u00ae Pharmaceuticals, Inc. (NYSE American: NBY) announces that Justin Hall, CEO, will present a company overview at the virtual Sequire Biotechnology Conference on Thursday, February 2 at 2:30 p.m. Eastern time. To register for the event, visit the Sequire Biotechnology website. \u201cWe closed 2022 with one of our best quarters ever for Avenova\u00ae unit sales. Looking into 2023, we are increasing our focus on our safe, effective wound care products, which we expect will become an important contributor to our business,\u201d said Mr. Hall. \u201cWe are excited to share an update on our opportunities with investors attending this conference.\u201d An archived webcast of the … <\/p>\n

Continue reading “NovaBay Pharmaceuticals to Present at the Virtual Sequire Biotechnology Conference on February 2, 2023”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-727029","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nNovaBay Pharmaceuticals to Present at the Virtual Sequire Biotechnology Conference on February 2, 2023 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/novabay-pharmaceuticals-to-present-at-the-virtual-sequire-biotechnology-conference-on-february-2-2023\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"NovaBay Pharmaceuticals to Present at the Virtual Sequire Biotechnology Conference on February 2, 2023 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"NovaBay Pharmaceuticals to Present at the Virtual Sequire Biotechnology Conference on February 2, 2023 EMERYVILLE, Calif.–(BUSINESS WIRE)–NovaBay\u00ae Pharmaceuticals, Inc. (NYSE American: NBY) announces that Justin Hall, CEO, will present a company overview at the virtual Sequire Biotechnology Conference on Thursday, February 2 at 2:30 p.m. Eastern time. To register for the event, visit the Sequire Biotechnology website. \u201cWe closed 2022 with one of our best quarters ever for Avenova\u00ae unit sales. Looking into 2023, we are increasing our focus on our safe, effective wound care products, which we expect will become an important contributor to our business,\u201d said Mr. Hall. \u201cWe are excited to share an update on our opportunities with investors attending this conference.\u201d An archived webcast of the … Continue reading "NovaBay Pharmaceuticals to Present at the Virtual Sequire Biotechnology Conference on February 2, 2023"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/novabay-pharmaceuticals-to-present-at-the-virtual-sequire-biotechnology-conference-on-february-2-2023\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2023-01-31T11:53:01+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20230131005342r1&sid=flmnd&distro=nx&lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/novabay-pharmaceuticals-to-present-at-the-virtual-sequire-biotechnology-conference-on-february-2-2023\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/novabay-pharmaceuticals-to-present-at-the-virtual-sequire-biotechnology-conference-on-february-2-2023\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"NovaBay Pharmaceuticals to Present at the Virtual Sequire Biotechnology Conference on February 2, 2023\",\"datePublished\":\"2023-01-31T11:53:01+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/novabay-pharmaceuticals-to-present-at-the-virtual-sequire-biotechnology-conference-on-february-2-2023\\\/\"},\"wordCount\":738,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/novabay-pharmaceuticals-to-present-at-the-virtual-sequire-biotechnology-conference-on-february-2-2023\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20230131005342r1&sid=flmnd&distro=nx&lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/novabay-pharmaceuticals-to-present-at-the-virtual-sequire-biotechnology-conference-on-february-2-2023\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/novabay-pharmaceuticals-to-present-at-the-virtual-sequire-biotechnology-conference-on-february-2-2023\\\/\",\"name\":\"NovaBay Pharmaceuticals to Present at the Virtual Sequire Biotechnology Conference on February 2, 2023 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/novabay-pharmaceuticals-to-present-at-the-virtual-sequire-biotechnology-conference-on-february-2-2023\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/novabay-pharmaceuticals-to-present-at-the-virtual-sequire-biotechnology-conference-on-february-2-2023\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20230131005342r1&sid=flmnd&distro=nx&lang=en\",\"datePublished\":\"2023-01-31T11:53:01+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/novabay-pharmaceuticals-to-present-at-the-virtual-sequire-biotechnology-conference-on-february-2-2023\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/novabay-pharmaceuticals-to-present-at-the-virtual-sequire-biotechnology-conference-on-february-2-2023\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/novabay-pharmaceuticals-to-present-at-the-virtual-sequire-biotechnology-conference-on-february-2-2023\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20230131005342r1&sid=flmnd&distro=nx&lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20230131005342r1&sid=flmnd&distro=nx&lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/novabay-pharmaceuticals-to-present-at-the-virtual-sequire-biotechnology-conference-on-february-2-2023\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"NovaBay Pharmaceuticals to Present at the Virtual Sequire Biotechnology Conference on February 2, 2023\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"NovaBay Pharmaceuticals to Present at the Virtual Sequire Biotechnology Conference on February 2, 2023 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/novabay-pharmaceuticals-to-present-at-the-virtual-sequire-biotechnology-conference-on-february-2-2023\/","og_locale":"en_US","og_type":"article","og_title":"NovaBay Pharmaceuticals to Present at the Virtual Sequire Biotechnology Conference on February 2, 2023 - Market Newsdesk","og_description":"NovaBay Pharmaceuticals to Present at the Virtual Sequire Biotechnology Conference on February 2, 2023 EMERYVILLE, Calif.–(BUSINESS WIRE)–NovaBay\u00ae Pharmaceuticals, Inc. (NYSE American: NBY) announces that Justin Hall, CEO, will present a company overview at the virtual Sequire Biotechnology Conference on Thursday, February 2 at 2:30 p.m. Eastern time. To register for the event, visit the Sequire Biotechnology website. \u201cWe closed 2022 with one of our best quarters ever for Avenova\u00ae unit sales. Looking into 2023, we are increasing our focus on our safe, effective wound care products, which we expect will become an important contributor to our business,\u201d said Mr. Hall. \u201cWe are excited to share an update on our opportunities with investors attending this conference.\u201d An archived webcast of the … Continue reading \"NovaBay Pharmaceuticals to Present at the Virtual Sequire Biotechnology Conference on February 2, 2023\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/novabay-pharmaceuticals-to-present-at-the-virtual-sequire-biotechnology-conference-on-february-2-2023\/","og_site_name":"Market Newsdesk","article_published_time":"2023-01-31T11:53:01+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20230131005342r1&sid=flmnd&distro=nx&lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/novabay-pharmaceuticals-to-present-at-the-virtual-sequire-biotechnology-conference-on-february-2-2023\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/novabay-pharmaceuticals-to-present-at-the-virtual-sequire-biotechnology-conference-on-february-2-2023\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"NovaBay Pharmaceuticals to Present at the Virtual Sequire Biotechnology Conference on February 2, 2023","datePublished":"2023-01-31T11:53:01+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/novabay-pharmaceuticals-to-present-at-the-virtual-sequire-biotechnology-conference-on-february-2-2023\/"},"wordCount":738,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/novabay-pharmaceuticals-to-present-at-the-virtual-sequire-biotechnology-conference-on-february-2-2023\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20230131005342r1&sid=flmnd&distro=nx&lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/novabay-pharmaceuticals-to-present-at-the-virtual-sequire-biotechnology-conference-on-february-2-2023\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/novabay-pharmaceuticals-to-present-at-the-virtual-sequire-biotechnology-conference-on-february-2-2023\/","name":"NovaBay Pharmaceuticals to Present at the Virtual Sequire Biotechnology Conference on February 2, 2023 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/novabay-pharmaceuticals-to-present-at-the-virtual-sequire-biotechnology-conference-on-february-2-2023\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/novabay-pharmaceuticals-to-present-at-the-virtual-sequire-biotechnology-conference-on-february-2-2023\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20230131005342r1&sid=flmnd&distro=nx&lang=en","datePublished":"2023-01-31T11:53:01+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/novabay-pharmaceuticals-to-present-at-the-virtual-sequire-biotechnology-conference-on-february-2-2023\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/novabay-pharmaceuticals-to-present-at-the-virtual-sequire-biotechnology-conference-on-february-2-2023\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/novabay-pharmaceuticals-to-present-at-the-virtual-sequire-biotechnology-conference-on-february-2-2023\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20230131005342r1&sid=flmnd&distro=nx&lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20230131005342r1&sid=flmnd&distro=nx&lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/novabay-pharmaceuticals-to-present-at-the-virtual-sequire-biotechnology-conference-on-february-2-2023\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"NovaBay Pharmaceuticals to Present at the Virtual Sequire Biotechnology Conference on February 2, 2023"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/727029","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=727029"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/727029\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=727029"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=727029"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=727029"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}